EGFR

Epidermal growth factor receptor (EGFR; HER-1) is expressed in the whole epidermis of normal skin. Additionally, aberrant EGFR activity is linked to a wide range of solid tumors. Overexpression of EGFR, often combined with EGFR mutations that cause hyper-activity, are linked to rapid growth of tumor cells. As a result, EGFR and EGFR-signaling is an attractive target for more specific cancer therapies. Several anti-EGFR monoclonal antibodies have already been clinically approved. Additionally, much work on developing antibody drug conjugates and chemotherapeutic nanoparticles use EGFR as a target.

Imanis EGFR tumor antigen cell lines are generated from well-characterized tumor models and engineered to alter their expression of EGFR. More cell lines to be added soon.